Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry

被引:53
作者
Ishibe, N [1 ]
Sgambati, MT [1 ]
Fontaine, L [1 ]
Goldin, LR [1 ]
Jain, N [1 ]
Weissman, N [1 ]
Marti, GE [1 ]
Caporso, NE [1 ]
机构
[1] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA
基金
美国国家卫生研究院;
关键词
pedigrees; familial; B-CLL; sporadic; descriptive; clinical;
D O I
10.3109/10428190109097681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In an ongoing study, families with two or more living cases of B-CLL in first-degree relatives have been recruited through physician and self-referral. Since 1967, 28 kindreds with 73 cases of B-CLL have been enrolled within the National Cancer Institute (NCI) Familial B-CLL Registry. Medical, clinical, and demographic information have been obtained from private physicians, patient interview, hospital records, and death certificates. We used SEER Registry data to compare characteristics of sporadic B-CLL to familial B-CLL. The mean age at diagnosis was approximately 10 years younger among familial cases (57.9 +/- 12.1) than that observed in sporadic cases (70.1 +/- 11.9). A higher percentage of second primary rumors among familial CLL cases compared to reports in sporadic was also observed (16% vs. 8.8%). However, the transformation rate to non-Hodgkin's lymphoma does not appear to be different from that reported for sporadic cases. In conclusion, we observed some differences between familial and sporadic cases; whether any of these characteristics affect survival time or severity of disease is unknown. The study of families with multiple B-CLL cases will aid in delineating the genes and environmental factors that may play a role in the development of both forms of B-CLL.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 36 条
[1]   CHRONIC LYMPHOCYTIC LEUKEMIAS AND NON-HODGKINS-LYMPHOMAS BY HISTOLOGICAL TYPE IN FARMING-ANIMAL BREEDING WORKERS - A POPULATION CASE-CONTROL STUDY BASED ON JOB TITLES [J].
AMADORI, D ;
NANNI, O ;
FALCINI, F ;
SARAGONI, A ;
TISON, V ;
CALLEA, A ;
SCARPI, E ;
RICCI, M ;
RIVA, N ;
BUIATTI, E .
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1995, 52 (06) :374-379
[2]  
BATATA A, 1993, CANCER, V71, P2732, DOI 10.1002/1097-0142(19930501)71:9<2732::AID-CNCR2820710908>3.0.CO
[3]  
2-Z
[4]   FAMILIAL CHRONIC LYMPHOCYTIC LEUKEMIA - IMMUNOLOGICAL AND CELLULAR CHARACTERIZATION [J].
BLATTNER, WA ;
STROBER, W ;
MUCHMORE, AV ;
BLAESE, RM ;
BRODER, S ;
FRAUMENI, JF .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (05) :554-557
[5]  
BROKSIMONI F, 1987, LANCET, V1, P329
[6]   Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias [J].
Cheson, BD ;
Vena, DA ;
Barrett, J ;
Freidlin, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2454-2460
[7]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[8]   INCREASED INCIDENCE OF HEMATOLOGIC MALIGNANCIES IN 1ST-DEGREE RELATIVES OF PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
CUTTNER, J .
CANCER INVESTIGATION, 1992, 10 (02) :103-109
[9]  
Denes AE, 1998, AM J HEMATOL, V58, P239, DOI 10.1002/(SICI)1096-8652(199807)58:3<239::AID-AJH14>3.0.CO
[10]  
2-4